Micell's Optimism In MiStent Biosorbable Polymer Stent Grows With Retrospective Study
A retrospective propensity-matched comparison of Micell’s MiStent sirolimus-eluting absorbable polymer coronary stent system to Abbott’s popular Xience V everolimus-eluting stent suggests that MiStent has a good chance of outperforming Xience in the DESSOLVE III randomized trial.
You may also be interested in...
The EuroPCR conference in Paris is the most important annual interventional cardiology conference in Europe and this year's edition brought more data from clinical trials of both established catheter-based technologies and innovative new devices.
Attention must be paid when withdrawal is for NDA approved in 1948 for brand synonymous with nonprescription pain relief, Bufferin. Even when FDA’s decision amounts to NDA database recordkeeping, withdrawal of application demands notice in US OTC space.
Access to expedited regulatory pathways, marketing exclusivity and tax credits in exchange for enrolling and retaining diverse clinical trial populations could provide a ‘carrot’ to the ‘stick’ in US FDA guidance and legislative proposals; attorneys Sarah Thompson Schick and Winston Kirton also call for a re-examination of concerns about remuneration for trial participants.